Adrian Newman-Tancredi
is co-founder and
Chief Scientific Officer
Neurolixis Inc.



Adrian Newman-Tancredi, PhD, DSc, gave an invited lecture on Monday 19 January 2015 at the highly-recognized School of Physiology and Pharmacology of Bristol University (UK). The...Read More
Neurolixis, a bioscience company co-founded by Adrian Newman-Tancredi, has announced a drug discovery collaboration with Jagiellonian University in Krakow, Poland. The collaboration...Read More
Adrian Newman-Tancredi will be chairing a session at the World Orphan Drug Congress in Brussels, Belgium, on 12th to 14th October 2014. Dr. Newman-Tancredi has been invited to chair...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.




    NeuroAct Communication

    offers professional and independent advice

    at each stage of early CNS drug discovery. 


    Consulting Services




    Read the latest news from NeuroAct Communication



    November 2014

    April 2014




    NeuroAct Communication  

    was founded by Adrian Newman-Tancredi PhD DSc

    an experienced industrial neuropharmacologist.


    Executive Profile




    Expertise in CNS Drug Discovery

    Preclinical pharmacology of antipsychotics,
    antidepressants, anti-Parkinsonian drugs and analgesics.   


    Read more